# GeneIII

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneiii

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.geneiii.com.cn
- Total disclosed funding: $3.5M
- Latest round: Series A (Jul 16, 2025)
- Investors on record: 2

## About

Based in Nanjing, China, and established in 2021, GeneIII engages in the development and commercialization of synthetic biology applications in the health and wellness sectors. The company was founded by a team led by Dr. Wang, a biomedical postdoctoral researcher from the University of Illinois Urbana-Champaign, and is composed of a highly educated workforce, with 60% holding postgraduate degrees. In July 2025, GeneIII raised CNY 25.00 million in series A funding from new investors Gaoxin Capital and Tuoxin Pharmaceutical.

GeneIII operates two main product lines: skincare bioactive raw materials and products, and dietary supplement ingredients and products. Its skincare range includes skin serum, wrinkle-reducing serum, hydrolyzed sodium hyaluronate, and ergothioneine, while its dietary supplements feature ergothioneine oral capsules, amaranth probiotic drinks, probiotics, and cold-pack gels targeting rhinitis.

The company generates revenue through the sale of its skincare and dietary supplement products, both directly and via business partnerships.

GeneIII plans to use its recent funding to further advance synthetic biology R&D and expand the application of ergothioneine in both functional skincare and nutraceutical segments.

## Funding rounds

- Series A, Jul 16, 2025, $3.5M — Gaoxin Capital, Tuoxin Pharmaceutical

## Investors

- Gaoxin Capital — Series A
- Tuoxin Pharmaceutical — Series A